Hormone Refractory Prostate Cancer Therapeutics
1. Plenaxis patent expiration
Treatment: Use in the treatment of men with advanced symptomatic prostate cancer
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968895 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(9 years ago) | |
| US6455499 | SPECIALITY EUROPEAN | Methods for treating disorders associated with LHRH activity |
Jun, 2015
(10 years ago) | |
| US6180608 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(9 years ago) | |
| US5843901 | SPECIALITY EUROPEAN | LHRH antagonist peptides |
Dec, 2015
(10 years ago) | |
| US6423686 | SPECIALITY EUROPEAN | LHRH antagonist peptides |
Jun, 2015
(10 years ago) | |
| US6699833 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(9 years ago) | |
Drugs and Companies using ABARELIX ingredient
Market Authorisation Date: 25 November, 2003
Dosage: INJECTABLE
More Information on Dosage
PLENAXIS family patents
